Patients were randomized to receive ranibizumab on day 1 , month 1 , and thereafter as needed guided by VA stabilization criteria ( group I , n = 106 ) ; ranibizumab on day 1 and thereafter as needed guided by disease activity criteria ( group II , n = 116 ) ; or vPDT on day 1 and disease activity treated with ranibizumab or vPDT at investigators ' discretion from month 3 ( group III , n = 55 ) .